Press release – For immediate release – 05:45 pm CEST
Median Technologies has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world, and selected to implement their clinical trial imaging strategy on some key oncology indications
- This is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company.
- The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years.
- This partnership will contribute to sustain Median’s future bookings and revenues growth.
The goal for this large pharmaceutical company is to improve operational execution, garnering faster results with a leaner methodology. Median will deliver imaging services for a portion of the client’s oncology Phase III trials.
The award came after an intensive bidding process and the renegotiation of the terms of the MSA with this client who has one of the largest pipelines in oncology. It is a recognition of Median’s performance, quality, and competitiveness for imaging services.
“We started to develop a relationship with this major pharmaceutical company several years ago, adapting our imaging workflow and technology to their specific needs while satisfying stringent processes to meet their quality standards. We are very pleased with this demonstration of trust, that takes our relationship to an entirely different level”, highlights Nicolas Dano, COO of the iCRO Business Unit at Median. “This partnership will contribute to sustain our future bookings and revenue growth, and we plan to replicate similar deals with other pharmaceutical companies”, he adds.
“We are thrilled to strengthen our collaboration with this major pharma client and to contribute, more than ever, to the industry effort to develop new oncology drugs that will save patients’ lives. An important differentiating factor was also our clinical, scientific, and artificial intelligence expertise”, adds Fredrik Brag, CEO and founder of Median Technologies.
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered software as medical device help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.